Author Archive: BIOtechNOW Editor

De-Mystifying Trade Agreements

shutterstock_13529329

To many people in our industry, international trade agreements may seem like esoteric documents that have little relevance to the day-to-day workings of a research-based, innovative enterprise. After all, aren’t these agreements more about the cross-border trade of big-ticket goods like autos and wheat than they are about new, cutting edge technologies? Well, actually no. Those who have been paying close attention know that these agreements define many of the underlying rules of the road Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Principles on Clinical Trial Data Sharing Reaffirm Commitment

cells115x76

BIO member companies will honor, at minimum, the following commitments: REGISTERING CLINICAL TRIALS: BIO member companies will register all company-sponsored clinical trials conducted in patients in an appropriate public registry, such as ClinicalTrials.gov or the European Clinical Trials Database (EudraCT). SUMMARIZING THE RESULTS OF CLINICAL TRIALS: BIO member companies will post technical summary results in a clinical trials database as follows: For approved products, all company sponsored clinical trials testing both safety and efficacy in Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Wednesday Keynote Luncheon

hrc115x76

Wednesday Keynote Luncheon Today noon-1:30 Hillary Rodham Clinton served as the 67th U.S. Secretary of State from 2009 until 2013, after nearly four decades in public service. Her “smart power” approach to foreign policy repositioned American diplomacy and development for the 21st century. Clinton played a central role in restoring America’s standing in the world, reasserting the United States as a Pacific power, imposing crippling sanctions on Iran and North Korea, responding to the Arab Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

The Most Linked In Man in Biotech Retires after 35 Years

Chris Y

The biotech world loses one of its preeminent titans of business development this year with the retirement of Chris Yochim. Variously dubbed “the face of AstraZeneca”, “Mr. Conference”, and other monikers as colorful as his dress shirts, Chris concludes a career spanning 35 years in the pharmaceutical industry. Trained as a pharmacologist, he contributed to the identification of several candidate compounds that are marketed drugs today, but more than anything else, Chris is known as Read More >

Events  |  1 Comment  |  Email This Post
Tags: , , , , , , , ,

Patent Parameters

Untitled-1

Supreme Court Finds Naturally Occurring DNA to Be Patent Ineligible Last summer, the Supreme Court issued its decision in Association for Molecular Pathology v. Myriad Genetics, Inc., which concerned the patent eligibility of the BRCA1 and BRCA2 genes. In Myriad, a unanimous Supreme Court held that a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated. The Court also determined, albeit with one caveat, that Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,